ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Tetrabenazine: Drug information

Tetrabenazine: Drug information
(For additional information see "Tetrabenazine: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Depression and suicidality:

Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington disease. Anyone considering the use of tetrabenazine must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality, and should be instructed to report behaviors of concern promptly to the treating physician.

Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington disease. Tetrabenazine is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression.

Brand Names: US
  • Xenazine
Brand Names: Canada
  • APO-Tetrabenazine;
  • Nitoman;
  • PMS-Tetrabenazine
Pharmacologic Category
  • Central Monoamine-Depleting Agent;
  • Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Dosing: Adult
Huntington disease–associated chorea

Huntington disease–associated chorea:

Initial: Oral: 12.5 mg once daily in the morning; may increase to 12.5 mg twice daily after 1 week. May increase daily dosage by 12.5 mg increments at weekly intervals up to 50 mg/day; divide daily doses >37.5 mg into 3 doses (maximum single dose: 25 mg).

Patients with chorea on 50 mg/day: Genotype for CYP2D6: Extensive/intermediate metabolizers: Oral: Maximum: 100 mg/day; 37.5 mg/dose.

Tardive dyskinesia

Tardive dyskinesia (off-label use) (alternative agent): Oral: Initial: 50 mg/day in divided doses; may increase daily dose by 50 mg increments every 2 weeks up to maximum of 150 mg/day in divided doses (Ref).

Alternatively, an initial dose of 25 to 37.5 mg/day in 2 or 3 divided doses has been recommended with increases or decreases in increments of 12.5 mg/day at weekly intervals. Usual maximum tolerated dose: 75 mg/day in 3 divided doses; in very rare cases, doses up to 200 mg/day have been used (Ref).

Tourette syndrome

Tourette syndrome (Canadian labeling): Initial: Oral: 12.5 mg 2 to 3 times daily; may increase daily dose by 12.5 mg increments at weekly intervals. Usual maximum tolerated dosage: 25 mg 3 times daily; maximum recommended dose: 200 mg/day.

Missed doses: If treatment is interrupted for >5 days, retitration is recommended. If treatment is interrupted for <5 days resume at previous maintenance dose.

Discontinuation of treatment: Treatment may be discontinued without tapering; chorea re-emergence may occur within 12 to 18 hours after the last dose.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

Use is contraindicated.

Dosing: Adjustment for Toxicity: Adult

For adverse reactions, including akathisia, restlessness, parkinsonism, insomnia, depression, suicidality, anxiety, sedation (intolerable): Suspend upward dosage titration and reduce dose; consider discontinuing therapy or treating symptoms if adverse reaction does not resolve (may be discontinued without tapering).

Dosing: Older Adult

Refer to adult dosing; use with caution.

Dosing: Pediatric
Tourette syndrome

Tourette syndrome (Canadian labeling): Children and Adolescents: Oral: Administer 50% of adult dose. Initial: 6.25 mg 2 to 3 times daily; may be increased by 6.25 mg daily at weekly intervals; should be titrated slowly to maximal tolerated and effective dose (dose is individualized).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing adjustment for toxicity: Children and Adolescents: For toxicity/adverse reaction, including akathisia, restlessness, parkinsonism, insomnia, depression, suicidality, anxiety, sedation (intolerable): Suspend upward dosage titration and reduce dose; consider discontinuing if adverse reaction does not resolve (may be discontinued without tapering).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Pediatric

Use is contraindicated.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Many adverse effects are dose-related and may resolve at lower dosages. Adverse effects reported for adults with chorea associated with Huntington disease.

>10%:

Central nervous system: Drowsiness (≤17% to ≤57%), sedation (≤17% to ≤57%), depression (19% to 35%), extrapyramidal reaction (15% to 33%), fatigue (22%), insomnia (22%), akathisia (19% to 20%), anxiety (15%), falling (15%)

Gastrointestinal: Nausea (13%)

Respiratory: Upper respiratory tract infection (11%)

1% to 10%:

Central nervous system: Drug-induced Parkinson's disease (3% to 10%), equilibrium disturbance (9%), irritability (9%), abnormal gait (4%), dizziness (4%), dysarthria (4%), headache (4%), obsessive rumination (4%)

Gastrointestinal: Dysphagia (4% to 10%), vomiting (6%), decreased appetite (4%), diarrhea (2%)

Genitourinary: Dysuria (4%)

Hematologic & oncologic: Bruise (6%)

Neuromuscular & skeletal: Bradykinesia (9%)

Respiratory: Bronchitis (4%), dyspnea (4%)

Miscellaneous: Laceration (6%, head)

<1%, postmarketing, and/or case reports: Aggressive behavior (worsening), aspiration pneumonia, confusion, hyperhidrosis, hyperprolactinemia, increased serum transaminases, orthostatic dizziness, orthostatic hypotension, neuroleptic malignant syndrome, pneumonia, prolonged QT interval on ECG, restlessness, skin rash, suicidal ideation, syncope, tremor

Contraindications

Hepatic impairment; active suicidality or untreated or inadequately treated depression; coadministration of monoamine oxidase inhibitors (MAOIs) or use of tetrabenazine within 2 weeks of discontinuation of MAOI therapy; coadministration with reserpine, ≥20 days should pass after discontinuing reserpine before initiating tetrabenazine therapy; coadministration with deutetrabenazine or valbenazine.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to tetrabenazine or any component of the formulation; history or current episode of clinical depression unless under the care of a psychiatrist who is familiar with the patient's disorder and tetrabenazine’s pharmacology.

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). If sedation occurs during treatment, dosage reduction or discontinuation may be necessary.

• Depression/suicidal ideation: Use can increase risk for depression and suicidal thoughts and behavior in patients with Huntington disease. Dosage reduction, treatment of depression, or discontinuation may be necessary.

• Esophageal dysmotility/aspiration: Use has been associated with esophageal dysmotility, dysphagia, and aspiration; use with caution in patients at risk of aspiration pneumonia.

• Neuroleptic malignant syndrome: Use may be associated with neuroleptic malignant syndrome (NMS). Discontinue with confirmed NMS; may recur with reintroduction of treatment; monitor carefully.

• Ophthalmic effects: Binds to melanin-containing tissues in animal studies; may result in accumulation and toxicity with extended use and long-term ophthalmic effects. Clinical relevance and monitoring recommendations are unknown.

• Orthostatic hypotension: May cause orthostatic hypotension; monitor patients at risk closely.

• Parkinsonism: May cause parkinsonism symptoms (ie, bradykinesia, hypertonia, rigidity). Dose reduction, treatment of parkinsonism, or discontinuation of therapy may be necessary.

• Psychomotor stimulation: Use has been associated with akathisia, restless, and agitation. Dosage reduction, treatment of psychomotor effects, or discontinuation may be necessary.

• QT prolongation: Has been shown to prolong the QT interval alone (minimal) and with other drugs with comparable effects on the QT interval (additive). Avoid use in patients with congenital QT prolongation, a history of cardiac arrhythmias, or concomitant drugs known to cause QT prolongation.

• Tardive dyskinesia: May cause dyskinetic movements; discontinue use if signs and symptoms of tardive dyskinesia occur.

Disease-related concerns:

• Prolactin-dependent tumors: Elevates prolactin levels; use with caution in patients with breast cancer or other prolactin-dependent tumors; dose discontinuation may be considered.

Special populations:

• CYP2D6 poor metabolizers: CYP2D6 poor metabolizers have increased levels of primary drug metabolites. Patients should be tested for the CYP2D6 gene prior to initiating doses >50 mg/day.

• Huntington disease: May worsen mood, cognition, rigidity, and functional capacity in patients with Huntington disease, which can be difficult to differentiate from progression of the underlying disease. Underlying chorea may improve over time in some patients, thereby decreasing the need for therapy. Re-evaluate patients need for treatment by periodically assessing the effect on chorea and possible adverse effects. Dose reduction or discontinuation of therapy may be necessary.

Other warnings/precautions:

• Appropriate use: Should not be used to treat levodopa-induced dyskinesia.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Xenazine: 12.5 mg [contains corn starch]

Xenazine: 25 mg [scored; contains corn starch]

Generic: 12.5 mg, 25 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Tetrabenazine Oral)

12.5 mg (per each): $15.70 - $78.81

25 mg (per each): $31.39 - $157.62

Tablets (Xenazine Oral)

12.5 mg (per each): $227.88

25 mg (per each): $455.76

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Nitoman: 25 mg [contains corn starch]

Generic: 25 mg

Administration: Adult

Oral: May administer without regard to meals.

Administration: Pediatric

Oral: Nitroman [Canadian labeling]: Administer without regard to meals.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:

Xenazine: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf#page=24

Use: Labeled Indications

Chorea associated with Huntington disease: Treatment of chorea associated with Huntington disease

Canadian labeling: Additional use (not in US labeling):Treatment of chronic tic disorders, including Tourette syndrome

Use: Off-Label: Adult

Tardive dyskinesia

Metabolism/Transport Effects

Substrate of CYP2D6 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Antipsychotic Agents: Tetrabenazine may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased. Risk C: Monitor therapy

Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the adverse/toxic effect of Tetrabenazine. Risk X: Avoid combination

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

CYP2D6 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Risk C: Monitor therapy

CYP2D6 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Management: Limit the tetrabenazine dose to 50 mg per day (25 mg per single dose) in patients taking strong CYP2D6 inhibitors. Risk D: Consider therapy modification

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Deutetrabenazine: May enhance the adverse/toxic effect of Tetrabenazine. Risk X: Avoid combination

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Levodopa-Foslevodopa: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors may diminish the therapeutic effect of Levodopa-Foslevodopa. Management: Consider alternatives to the coadministration of levodopa and vesicular monoamine transporter 2 (VMAT2) inhibitors. If combined, monitor for reduced levodopa efficacy. Risk D: Consider therapy modification

Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the adverse/toxic effect of Tetrabenazine. Risk X: Avoid combination

MetyroSINE: May enhance the adverse/toxic effect of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: Tetrabenazine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Risk X: Avoid combination

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: Tetrabenazine may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Tetrabenazine. Risk X: Avoid combination

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QuiNIDine: Tetrabenazine may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Management: Limit the tetrabenazine dose to 50 mg per day (25 mg per single dose) in patients taking quinidine. Additionally, monitor for QTc interval prolongation and ventricular arrhythmias (including torsades de pointes) when these drugs are combined. Risk D: Consider therapy modification

Reserpine: May enhance the adverse/toxic effect of Tetrabenazine. Risk X: Avoid combination

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Valbenazine: Tetrabenazine may enhance the adverse/toxic effect of Valbenazine. Risk X: Avoid combination

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Pregnancy Considerations

Adverse events were observed in some animal reproduction studies. Limited information related to the use of tetrabenazine in pregnancy has been located (Lubbe 1983).

Breastfeeding Considerations

It is not known if tetrabenazine is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Monitoring Parameters

Liver function (baseline and as clinically indicated); orthostatic BP (as clinically indicated); CYP2D6 genotyping for evaluation of metabolizer status (for patients requiring >50 mg/day); EKG (as clinically indicated for QT prolongation); signs/symptoms of suicidal ideation.

Mechanism of Action

Acts as a reversible inhibitor of the human vesicular monamine transporter type 2 (VMAT-2) and thereby decreases the uptake of monoamines (including dopamine, serotonin, norepinephrine, and histamine) into synaptic vesicles and depletes the monoamine stores; hydroxytetrabenazine (HTBZ) also inhibits VMAT-2; weak binding affinity for dopamine D2 receptors.

Pharmacokinetics (Adult Data Unless Noted)

Duration: 16 to 24 hours (at steady-state); chorea may recur within 12 to 18 hours after discontinuation

Protein binding: 82% to 85%; Metabolites: 59% to 68%

Metabolism: Hepatic (rapid and extensive), to active metabolites: Alpha and beta hydroxytetrabenazine (HTBZ) via CYP2D6 (primary active moiety)

Bioavailability: Low and erratic (due to extensive first-pass effects); unaffected by food

Half-life elimination: Alpha-HTBZ: 7 hours, 10 hours (hepatic impairment); Beta-HTBZ: 5 hours, 8 hours (hepatic impairment); Terabenazine: ~17.5 hours (hepatic impairment)

Time to peak, plasma: Metabolites: Within 1 to 1.5 hours

Excretion: Urine (~75% as metabolites, <10% as alpha and beta HTBZ); feces (~7% to 16%)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Metabolism of tetrabenazine is decreased in patients with hepatic function impairment and the Cmax is 7- to 190-fold higher compared with healthy subjects.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Tetmodis | Xenazine;
  • (AR) Argentina: Feinardon | Tetrabenz | Tetrazol | Trenazin;
  • (AT) Austria: Dystardis | Tetmodis | Tetrabenazin aristo;
  • (AU) Australia: Tetrabenazine sun;
  • (BD) Bangladesh: Revocon | Tetraben | Tetrazin;
  • (BG) Bulgaria: Tetmodis;
  • (CH) Switzerland: Xenazine;
  • (CL) Chile: Tetmodis;
  • (CO) Colombia: Tetmodis | Tetrabex;
  • (CZ) Czech Republic: Tetmodis;
  • (DE) Germany: Dystardis | Nitoman | Tetmodis | Tetrabenazin aristo | Tetrabenazin neuraxpharm | Xenazine;
  • (EE) Estonia: Tetmodis | Xenazine;
  • (ES) Spain: Nitoman | Tetrabenazina aristo | Tetrabenazina sun;
  • (FI) Finland: Dystardis | Tetmodis;
  • (FR) France: Nitoman | Tetmodis | Xenazine;
  • (GB) United Kingdom: Nitoman | Revocon | Tardiben | Tetmodis | Tetrabenazine aristo | Xenazine;
  • (GR) Greece: Tetmodis | Xenazine;
  • (HK) Hong Kong: Nitomane;
  • (HU) Hungary: Motetis | Xenazine;
  • (IE) Ireland: Tetmodis | Xenazine;
  • (IL) Israel: Nitoman;
  • (IN) India: Revocon | Ticstop;
  • (IT) Italy: Tetrabenazina aristo | Tetrabenazina sun | Xenazina;
  • (JP) Japan: Choreazine;
  • (KR) Korea, Republic of: Xenazine;
  • (KW) Kuwait: Apo tetrabenazine;
  • (LB) Lebanon: Xenazine;
  • (LT) Lithuania: Tetmodis;
  • (LV) Latvia: Tetmodis;
  • (MX) Mexico: Tetmodis;
  • (MY) Malaysia: Revocon | Xenazine;
  • (NL) Netherlands: Tetmodis;
  • (NO) Norway: Nitoman | Tardiben | Tetmodis | Xenazine;
  • (NZ) New Zealand: Motetis | Xenazine;
  • (PE) Peru: Tetmodis;
  • (PL) Poland: Nitoman | Tetmodis | Xenazine;
  • (PR) Puerto Rico: Xenazine;
  • (PT) Portugal: Nitoman | Tetmodis;
  • (PY) Paraguay: Tetrabenazina tuteur;
  • (RO) Romania: Artesyd | Tetmodis;
  • (RU) Russian Federation: Normokineztine;
  • (SE) Sweden: Tetmodis | Xenazine;
  • (SI) Slovenia: Tetmodis | Xenazine;
  • (SK) Slovakia: Tetmodis;
  • (TN) Tunisia: Xenazine;
  • (TW) Taiwan: Nitoman;
  • (UY) Uruguay: Tetrazol;
  • (VE) Venezuela, Bolivarian Republic of: Tetmodis
  1. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-469. doi:10.1212/WNL.0b013e31829d86b6 [PubMed 23897874]
  2. Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J. 1971;4(5778):25-26. doi:10.1136/bmj.4.5778.25 [PubMed 4938245]
  3. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972;27(1):95-99. doi:10.1001/archpsyc.1972.01750250081011 [PubMed 4555831]
  4. Lubbe WF and Walker EB, "Chorea Gravidarum Associated With Circulating Lupus Anticoagulant Successful Outcome of Pregnancy With Prednisone and Aspirin Therapy. Case Report," Br J Obstet Gynaecol, 1983, 90(5):487-90. [PubMed 6405781]
  5. Nitoman (tetrabenazine) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; October 2020.
  6. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279-1281. doi:10.1176/ajp.156.8.1279 [PubMed 10450276]
  7. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388-399. doi:10.1177/0706743719828968 [PubMed 30791698]
  8. Xenazine (tetrabenazine) tablets [prescribing information]. Deerfield, IL: Lundbeck; June 2022.
Topic 9476 Version 334.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟